Sangaralingham S Jeson, McKie Paul M, Ichiki Tomoko, Scott Christopher G, Heublein Denise M, Chen Horng H, Bailey Kent R, Redfield Margaret M, Rodeheffer Richard J, Burnett John C
From the Cardiorenal Research Laboratory (S.J.S., P.M.M., T.I., D.M.H., H.H.C., M.M.R., J.C.B.), Divisions of Cardiovascular Diseases (S.J.S., P.M.M., T.I., D.M.H., H.H.C., M.M.R., R.J.R., J.C.B.), and Biomedical Statistics and Informatics (C.G.S., K.R.B.), Mayo Clinic, Rochester, MN.
Hypertension. 2015 Jun;65(6):1187-94. doi: 10.1161/HYPERTENSIONAHA.115.05366. Epub 2015 Apr 20.
C-type natriuretic peptide (CNP) is an endothelium-derived peptide that is released as a protective mechanism in response cardiovascular injury or disease. However, no studies have investigated circulating CNP, identifying clinical factors that may influence CNP and its relationship to cardiovascular disease in the general population. We studied 1841 randomly selected subjects from Olmsted County, MN (mean age, 63±11 years; 48% men). Plasma CNP was measured by a well-established radioimmunoassay and echocardiography, clinical characterization, and detailed medical record review were performed. We report that CNP circulates at various concentrations (median, 13 pg/mL), was unaffected by sex, was weakly associated by age, and that highest quartile of CNP identified a high-risk phenotype. Subjects with CNP in the highest quartile were associated with increased risk of myocardial infarction (multivariable-adjusted hazard ratio, 1.51; 95% confidence interval, 1.09-2.09; P=0.01) but not heart failure, cerebrovascular accidents, or death during a follow-up of 12 years. Addition of the highest quartile of CNP to clinical variables led to a modest increase in the integrated discrimination improvement for risk of myocardial infarction. In a large community-based cohort, elevated circulating CNP identified a high-risk phenotype that included cardiovascular comorbidities and left ventricular dysfunction, and provided evidence that highest concentrations of CNP potentially has prognostic value in predicting future risk of myocardial infarction. Together, these data from the general population highlight the potential value of CNP and support the need for additional studies to evaluate whether mechanisms regulating CNP could improve outcomes.
C型利钠肽(CNP)是一种内皮源性肽,作为对心血管损伤或疾病的一种保护机制而释放。然而,尚无研究调查循环中的CNP,确定可能影响CNP的临床因素及其与普通人群心血管疾病的关系。我们对明尼苏达州奥尔姆斯特德县随机选取的1841名受试者进行了研究(平均年龄63±11岁;48%为男性)。采用成熟的放射免疫分析法测定血浆CNP,并进行超声心动图检查、临床特征分析和详细的病历审查。我们报告称,CNP以不同浓度循环(中位数为13 pg/mL),不受性别影响,与年龄呈弱相关,且CNP最高四分位数确定了一种高危表型。CNP处于最高四分位数的受试者与心肌梗死风险增加相关(多变量调整风险比为1.51;95%置信区间为1.09 - 2.09;P = 0.01),但在12年的随访期间与心力衰竭、脑血管意外或死亡无关。将CNP最高四分位数添加到临床变量中,可使心肌梗死风险的综合判别改善略有增加。在一个大型社区队列中,循环CNP升高确定了一种包括心血管合并症和左心室功能障碍的高危表型,并提供了证据表明CNP的最高浓度在预测未来心肌梗死风险方面可能具有预后价值。总之,来自普通人群的这些数据突出了CNP的潜在价值,并支持需要进行更多研究以评估调节CNP的机制是否能改善预后。